Interstitial Lung Disease (ILD)

What “interstitial lung disease” actually means

ILD is not the same thing as IPF

This is the single most important distinction to understand about ILD, and it is also the most common point of confusion. Idiopathic pulmonary fibrosis, or IPF, is a specific, well-defined subtype of ILD: a progressive scarring disease of unknown cause with a particular pattern on imaging and, when needed, on tissue sampling.

IPF is one of the better-known and more extensively studied forms of ILD, which is part of why it sometimes gets used loosely as a stand-in for the entire category. But IPF is not a synonym for ILD as a whole, and treating it that way can lead to real misunderstandings about prognosis and treatment.

Many other forms of ILD are quite different from IPF, as the comparison below outlines.

IPF vs. Other Forms of ILD

IPF vs. Other Forms of ILD

Dimension	Idiopathic Pulmonary Fibrosis (IPF)	Many Other Forms of ILD
Underlying Process	Progressive scarring, or fibrosis	Often active inflammation that can improve substantially with treatment rather than irreversible scarring
Cause	Idiopathic, meaning of unknown cause	Often an identifiable trigger, such as an autoimmune condition or an inhaled exposure
Typical Course	Tends to worsen over time even with treatment, though the rate of progression varies a great deal	Varies considerably; some forms stabilize or even improve once the underlying cause is addressed
Diagnostic Basis	A particular pattern on imaging and, when needed, on tissue sampling	Pattern and category vary by subtype

Assuming that any case of ILD will behave like IPF, or that every case needs the same treatment as IPF, is inaccurate and can create unnecessary alarm or, in other cases, false reassurance.

The major categories of ILD

Rather than a single disease, ILD is better understood as several genuinely distinct groups of conditions, summarized above. These groups matter clinically because they carry different prognoses and treatment approaches, even when they look similar on any single test.

Connective-tissue-disease-associated ILD is typically managed alongside the underlying autoimmune condition, and exposure-related or medication-related forms often improve once the responsible trigger is identified and reduced. In a meaningful minority of cases, even a thorough evaluation cannot confidently assign a specific subtype; these cases are still managed based on the pattern of disease and how it behaves over time.

Common symptoms

The most common presenting symptoms across ILD subtypes, summarized above, are shortness of breath that develops gradually and shows up first during exertion, such as climbing stairs or walking briskly, and a persistent dry cough that lingers for weeks or months without an obvious cause.

Because both symptoms overlap with many other conditions, they are sometimes attributed to aging, deconditioning, or other causes before ILD is considered, which can delay diagnosis.

How ILD is diagnosed

Diagnosing ILD is a multi-step process that draws on several types of information, including a detailed history, imaging, and pulmonary function testing, because no single test reliably identifies the specific subtype on its own. The steps below outline how that evaluation typically unfolds.

The Diagnostic Pathway

1. 01→History and Exposure ReviewCovers the pace and pattern of symptoms, occupational and environmental exposures, hobbies, home environment, medication use, and family history of lung disease.↓
2. 02→High-Resolution CT (HRCT)Detailed, thin-slice chest imaging that can reveal specific patterns of scarring or inflammation; some patterns are distinctive enough to support a confident diagnosis on their own.↓
3. 03→Pulmonary Function TestingMeasures lung volumes and gas exchange. ILD classically produces a restrictive pattern, a different mechanical problem than the obstructive pattern seen in asthma or COPD.↓
4. 04Diffusion Capacity (DLCO)Estimates how well oxygen crosses from the air sacs into the bloodstream; frequently reduced in ILD, sometimes out of proportion to other test results.↓
5. 05→Exercise-Based Oxygen AssessmentA walk test with continuous pulse oximetry can identify oxygen desaturation that appears only with activity, useful for activity guidance and for determining whether supplemental oxygen is needed during exertion.↓
6. 06→Serologic and Clinical EvaluationBlood tests for autoimmune markers are added when the history, exam, or imaging pattern raises suspicion for a connective-tissue-disease-associated form.↓
7. 07→Lung Biopsy, When NeededIf the diagnosis remains uncertain after imaging, testing, and clinical evaluation, tissue sampling may be considered to further characterize the specific pattern of disease.↓
8. 08Multidisciplinary DiscussionWhen the picture remains unclear, pulmonology, radiology, and, when relevant, rheumatology and pathology review the case together to pin down the specific subtype.

Why multidisciplinary diagnosis matters

One of the most distinctive features of modern ILD care is that an accurate diagnosis frequently depends on a coordinated discussion among multiple specialists, rather than the judgment of a single physician working alone. Pulmonology, radiology, and, when relevant, rheumatology and pathology often review the same case together, weighing the history, imaging, and any tissue findings side by side.

This multidisciplinary approach matters because several ILD subtypes can genuinely resemble one another on any individual test. A pattern that looks like IPF on imaging might, on closer review with clinical and serologic information, turn out to be connective-tissue-disease-associated ILD instead.

Getting the specific subtype right is not an academic exercise. It meaningfully affects which treatment approach is likely to help, what course the disease is expected to follow, and how monitoring should be structured going forward.

Treatment depends on the subtype

There is no single, universal treatment for ILD, and it is worth stating this plainly because it is easy to assume otherwise. Because ILD subtypes differ so much in their underlying biology, treatment approaches diverge accordingly, as summarized above.

Antifibrotic medications are specifically used for progressive fibrotic patterns of lung disease, such as IPF, where the treatment goal is to slow the rate of scarring over time. These medications do not reverse existing scarring, and they are not the appropriate approach for inflammatory forms of ILD.

Anti-inflammatory and immunomodulatory approaches, which work by calming an overactive immune response, are more relevant for many inflammatory and connective-tissue-disease-associated forms of ILD, where inflammation, rather than established fibrosis, is the dominant process. In cases tied to a specific autoimmune condition, treatment often involves coordinating with rheumatology to manage both the underlying autoimmune disease and its effect on the lungs.

For exposure-related and medication-related ILD, identifying and reducing or removing the responsible exposure or medication is often a central part of management and can lead to meaningful improvement in some cases.

Because these approaches differ so substantially, and because using the wrong approach can be ineffective or even harmful, an accurate subtype diagnosis is the foundation that treatment decisions are built on.

Ongoing monitoring

ILD is generally a condition that requires ongoing follow-up rather than a single evaluation and treatment plan. Regular pulmonary function testing, along with clinical review of symptoms and periodic imaging, helps track whether the disease is stable, improving, or progressing over time.

Because the course of ILD varies significantly both by subtype and from one individual to another, the pace and intensity of monitoring are typically tailored to each person’s specific diagnosis and how their disease has behaved so far.

Monitoring visits typically compare current pulmonary function results against previous measurements to look for meaningful change, rather than judging any single test result in isolation. A gradual decline in lung volumes or diffusion capacity over successive visits can be an early signal that a treatment plan needs to be reconsidered, even before symptoms noticeably worsen. Conversely, stable results over time can be reassuring and support continuing the current approach.

This is one more reason why an accurate subtype diagnosis at the outset matters so much: it sets expectations for what “stable” or “progressing” should look like for that particular form of ILD, since the same numeric change can mean something very different in an inflammatory, potentially reversible process than in a progressive fibrotic one.

What this means day to day

Because ILD spans such a wide range of underlying conditions, its day-to-day impact varies considerably from person to person, as summarized above.

Staying current on routine vaccinations, avoiding tobacco smoke, and promptly addressing new or worsening respiratory symptoms are generally sensible steps for anyone living with ILD, since respiratory infections can have an outsized effect on already-affected lung tissue. None of this replaces subtype-specific treatment, but it is a reasonable complement to it.

Getting an accurate diagnosis

Because the distinction between ILD subtypes, and specifically between IPF and the many other forms of ILD, has such a direct effect on treatment and outlook, it is worth pursuing a thorough evaluation rather than accepting a general “ILD” or “pulmonary fibrosis” label without further characterization.

A careful history, appropriate testing, and, where needed, a multidisciplinary discussion give the clearest picture of which specific condition is actually present and which treatment approach is most likely to help.

For patients in the North Dallas-Fort Worth area, the pulmonary team at VitalAir Sleep & Lung Center in Frisco, Texas offers pulmonary function testing and evaluation for unexplained shortness of breath or persistent cough, which can be an appropriate starting point when ILD is a consideration.